Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ModCAR-Her2
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ModCAR-Her2 is a preclinical-stage modular chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio for the treatment of HER2-positive solid tumors, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The ModCAR platform utilizes a modular approach to CAR design, intended to enhance the precision and control of CAR cell activity against tumor cells expressing the Human Epidermal Growth Factor Receptor 2 (HER2). By targeting HER2, a well-validated oncogenic driver in various malignancies, ModCAR-Her2 aims to overcome the challenges of traditional CAR-T therapies in solid tumor environments, such as antigen heterogeneity and off-tumor toxicity.
- Other names
- ModCAR-HER2ModCAR-HER-2ModCAR-HER 2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ModCAR-Her2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ModCAR-Her2.